MedTrace Logo

Dapagliflozin on Volume Vascular Outcomes.

NCT04869124 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-11-12

No results posted yet for this study

Summary

The purpose of the DAPA-VOLVO trial is to investigate the effects of Dapagliflozin on top of recommended standard therapy on volume status and vascular function in clinically stable de novo or chronic heart failure patients after hospitalization because of an acute decompensated heart failure event.

Conditions

  • Heart Failure，Congestive

Interventions

DRUG

Dapagliflozin

Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.

DRUG

Placebo

Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Frank Ruschitzka

    lead OTHER

Principal Investigators

  • Frank Ruschitzka, M.D. · Cardiology, University Heart Center Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-15
Primary Completion
2024-09-26
Completion
2024-10-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04869124 on ClinicalTrials.gov